Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03377491
Registration number
NCT03377491
Ethics application status
Date submitted
6/12/2017
Date registered
19/12/2017
Date last updated
10/04/2023
Titles & IDs
Public title
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Query!
Scientific title
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Query!
Secondary ID [1]
0
0
EF-27
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pancreas Adenocarcinoma
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - NovoTTF-200T
Treatment: Drugs - Gemcitabine
Treatment: Drugs - nab paclitaxel
Experimental: NovoTTF-200T - Patients receive TTFields using the NovoTTF-200T System together with gemcitabine and nab-Paclitaxel
Active Comparator: Best Standard of Care - Patients receive best standard of care with gemcitabine and nab-Paclitaxel
Treatment: Devices: NovoTTF-200T
Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
Treatment: Drugs: Gemcitabine
Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
Treatment: Drugs: nab paclitaxel
nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
4 years
Query!
Secondary outcome [1]
0
0
Progression-free survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
4 years
Query!
Secondary outcome [2]
0
0
Local progression-free survival
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
4 years
Query!
Secondary outcome [3]
0
0
Objective response rate
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
4 years
Query!
Secondary outcome [4]
0
0
One-year survival rate
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
4 years
Query!
Secondary outcome [5]
0
0
Quality of life
Query!
Assessment method [5]
0
0
Quality of life will be assessed using the EORTC QLQ C-30 questionnaire with EORTC QLQ-PAN26 (Pancreatic Cancer symptom) supplement.
Query!
Timepoint [5]
0
0
4 years
Query!
Secondary outcome [6]
0
0
Pain-free survival
Query!
Assessment method [6]
0
0
Pain-free survival will measured as the duration between the time of randomization until a greater than or equal to two-point decline from a baseline measurement in a patient self-reported visual analogue scale (VAS) is recorded or death, whichever occurs first.
Query!
Timepoint [6]
0
0
4 years
Query!
Secondary outcome [7]
0
0
Puncture-free survival
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
4 years
Query!
Secondary outcome [8]
0
0
Resectability rate
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
4 years
Query!
Secondary outcome [9]
0
0
Toxicity profile
Query!
Assessment method [9]
0
0
Toxicity profile in patients treated with TTFields in combination with gemcitabine and nab-paclitaxel compared to the toxicity profile of patients treated with chemotherapy alone, measured by the rate of treatment-emergent toxicities in both arms. Adverse events will be collected and recorded based on the revised Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Query!
Timepoint [9]
0
0
4 years
Query!
Eligibility
Key inclusion criteria
1. 18 years of age and older
2. Life expectancy of = 3 months
3. Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas
4. Unresectable, locally advanced stage disease according to the following criteria:
- Head/uncinate process:
1. Solid tumor contact with SMA>180°
2. Solid tumor contact with the CA>180°
3. Solid tumor contact with the first jejunal SMA branch
4. Unreconstructible SMV/PV due to tumor involvement or occlusion (can be d/t
tumor or bland thrombus)
5. Contact with most proximal draining jejunal branch into SMV
- Body and tail
1. Solid tumor contact of >180° with the SMA or CA
2. Solid tumor contact with the CA and aortic involvement
3. Unreconstructible SMV/PV due to tumor involvement or occlusion (can be d/t
tumor or bland thrombus)
- No distant metastasis, including non-regional lymph node metastasis
- No borderline resectable (per Al-Hawary MM, et al., Radiology 201414)
5. ECOG score 0-2
6. Amenable and assigned by the investigator to receive therapy with gemcitabine and
nab-paclitaxel
7. Able to operate the NovoTTF-200T System independently or with the help of a caregiver
8. Signed informed consent form for the study protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Prior palliative treatment (e.g. surgery, radiation) to the tumor
2. Cancer requiring anti-tumor treatment within the 5 years before inclusion, excluding
treated stage I prostate cancer, in situ cervical or uterus cancer, in situ breast
cancer and non-melanomatous skin cancer.
3. Serious co-morbidities:
1. Clinically significant (as determined by the investigator) hematological, hepatic
and renal dysfunction, defined as: Neutrophil count < 1.5 x 10^9/L and platelet
count < 100 x 10^9/L; bilirubin > 1.5 x Upper Limit of Normal (ULN); AST and/or
ALT > 2.5 x ULN; and serum creatinine > 1.5 x ULN.
2. History of significant cardiovascular disease unless the disease is well
controlled. Significant cardiac disease includes second/third degree heart block;
significant ischemic heart disease; poorly controlled hypertension; congestive
heart failure of the New York Heart Association (NYHA) Class II or worse (slight
limitation of physical activity; comfortable at rest, but ordinary activity
results in fatigue, palpitation or dyspnea).
3. History of arrhythmia that is symptomatic or requires treatment. Patients with
atrial fibrillation or flutter controlled by medication are not excluded from
participation in the trial.
4. History of cerebrovascular accident (CVA) within 6 months prior to randomization
or that is not stable.
5. Active infection or serious underlying medical condition that would impair the
ability of the patient to receive protocol therapy.
6. History of any psychiatric condition that might impair patient's ability to
understand or comply with the requirements of the study or to provide consent.
4. Concurrent anti-tumor therapy beyond gemcitabine and nab-paclitaxel
5. Implantable electronic medical devices in the torso, such as pacemakers
6. Known severe hypersensitivities to medical adhesives or hydrogel, or to one of the
chemotherapies used in this trial.
7. Pregnancy or breast-feeding (female patients with reproductive potential and their
partners must accept to use effective contraception throughout the entire study period
and for 3 months after the end of treatment). All patients who are capable of becoming
pregnant must take a pregnancy test which is negative within 72 hours before beginning
treatment. The definition of effective contraception is left up to the decision of the
investigator.
8. Unable to follow the protocol for medical, psychological, familial, geographic or
other reasons.
9. Admitted to an institution by administrative or court order.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/02/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/10/2024
Query!
Actual
Query!
Sample size
Target
556
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,WA
Query!
Recruitment hospital [1]
0
0
Greenslopes Private Hospital - Greenslopes
Query!
Recruitment hospital [2]
0
0
St. John of God Murdoch Hospital - Murdoch
Query!
Recruitment hospital [3]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [4]
0
0
Sydney Adventist Hospital - Wahroonga
Query!
Recruitment hospital [5]
0
0
Westmead Hosptial - Westmead
Query!
Recruitment postcode(s) [1]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [2]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [3]
0
0
VIC 3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
NSW 2076 - Wahroonga
Query!
Recruitment postcode(s) [5]
0
0
NSW 2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maine
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Jersey
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oklahoma
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oregon
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Pennsylvania
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Tennessee
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Texas
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Washington
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
West Virginia
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Wörthersee
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Graz
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Salzburg
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Steyr
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Anderlecht
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Leuven
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Woluwe-Saint-Lambert
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Florianópolis
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Ijuí
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Porto Alegre
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Ribeirão Preto
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Rio De Janeiro
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
São Marcos
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
São Paulo
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Ontario
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Quebec
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Guangdong
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Heilongjiang
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Hubei
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Shaanxi
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Shandong
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Zhejiang
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Beijing
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Changchun
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Guangzhou
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Jilin
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Shanghai
Query!
Country [58]
0
0
China
Query!
State/province [58]
0
0
Shanxi
Query!
Country [59]
0
0
China
Query!
State/province [59]
0
0
Xingtai
Query!
Country [60]
0
0
China
Query!
State/province [60]
0
0
Zhengzhou
Query!
Country [61]
0
0
Croatia
Query!
State/province [61]
0
0
Zagreb
Query!
Country [62]
0
0
Czechia
Query!
State/province [62]
0
0
Brno Stred
Query!
Country [63]
0
0
Czechia
Query!
State/province [63]
0
0
Nový Jicín
Query!
Country [64]
0
0
Czechia
Query!
State/province [64]
0
0
Olomouc
Query!
Country [65]
0
0
Czechia
Query!
State/province [65]
0
0
Praha 2
Query!
Country [66]
0
0
Czechia
Query!
State/province [66]
0
0
Praha 8
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Bordeaux
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Angers cedex
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Lorient
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Lyon
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Paris
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Plérin
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Strasbourg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Chemnitz
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Hannover
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Landshut
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Lingen
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Merseburg
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
München
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Ulm
Query!
Country [81]
0
0
Hong Kong
Query!
State/province [81]
0
0
Hong Kong
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Budapest
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Gyula
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Kecskemét
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Szekszárd
Query!
Country [86]
0
0
Hungary
Query!
State/province [86]
0
0
Szolnok
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Haifa
Query!
Country [88]
0
0
Israel
Query!
State/province [88]
0
0
Petah tikva
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Ramat Gan
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Tel Aviv
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Alessandria
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Firenze
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Roma
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Torino
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Busan
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Gyeonggi-do
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Daegu
Query!
Country [98]
0
0
Korea, Republic of
Query!
State/province [98]
0
0
Hwasun
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Incheon
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Seongnam-si
Query!
Country [101]
0
0
Korea, Republic of
Query!
State/province [101]
0
0
Seoul
Query!
Country [102]
0
0
Korea, Republic of
Query!
State/province [102]
0
0
Suwon
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Chih.
Query!
Country [104]
0
0
Mexico
Query!
State/province [104]
0
0
NL
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Sinaloa
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Aguascalientes
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Cuauhtémoc
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Cuautitlán Izcalli
Query!
Country [109]
0
0
Mexico
Query!
State/province [109]
0
0
Estado De México
Query!
Country [110]
0
0
Mexico
Query!
State/province [110]
0
0
Monterrey
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
Puebla
Query!
Country [112]
0
0
Mexico
Query!
State/province [112]
0
0
San Luis Potosí
Query!
Country [113]
0
0
Mexico
Query!
State/province [113]
0
0
Toluca de Lerdo
Query!
Country [114]
0
0
Mexico
Query!
State/province [114]
0
0
Toluca De Lerdo
Query!
Country [115]
0
0
Mexico
Query!
State/province [115]
0
0
Veracruz
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Poznan
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Rzeszów
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Warsaw
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Wroclaw
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Barcelona
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Elche
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Madrid
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Málaga
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Pamplona
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Santander
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Valencia
Query!
Country [127]
0
0
Switzerland
Query!
State/province [127]
0
0
Fribourg
Query!
Country [128]
0
0
Switzerland
Query!
State/province [128]
0
0
Winterthur
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
NovoCure Ltd.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Brief Summary:
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy
and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and
nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The
device is an experimental, portable, battery operated device for chronic administration of
alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by
means of surface, insulated electrode arrays.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03377491
Query!
Trial related presentations / publications
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083.
Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5.
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.
Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26(7):633-40. doi: 10.1007/s10585-009-9262-y. Epub 2009 Apr 23.
Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep. 2015 Dec 11;5:18046. doi: 10.1038/srep18046.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.
Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, Cahal S, Kirson ED, Weinberg U, Palti Y. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology. 2014 Jan-Feb;14(1):54-63. doi: 10.1016/j.pan.2013.11.009. Epub 2013 Dec 4.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum In: JAMA. 2018 May 1;319(17):1824.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03377491
Download to PDF